Keywords: Probes & Targets, Molecular Imaging
Motivation: It is of great significance to predict the efficacy of immunotherapy at an early stage and avoid over-treatment of patients with low immune response.
Goal(s): Using molecular imaging technology to monitor the immunotherapy-related biomarkers is expected to predict the therapeutic effect of TNBC immunotherapy at an early stage.
Approach: The granzyme B-responsive MR/NIR fluorescent probe was constructed for molecular imaging.
Results: The MR/NIR fluorescence imaging showed that the probe was activated by granzyme B in tumor with immunotherapy or chemotherapy combined with immunotherapy.
Impact: Early prediction of the efficacy of immunotherapy is of great significance for optimizing the treatment plan in time and avoiding overtreatment of patients with low response.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords